Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311181 · ClinicalTrials.gov registry record · Phase 4
POWER (Pulse Width Optimized Waveform Evaluation Trial)
A Phase 4 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 4
- Development phase
- 217
- Enrollment target
NCT00311181 is a Phase 4 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 217 participants.
The verdict
NCT00311181, a Phase 4 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 217 participants
- Enrollment target
Study Summary
The objective of this study is to compare the ULV (Upper Limit of Vulnerability)/DFT (Defibrillation Threshold) efficacy between the 2.5, 3.5 and 4.5 ms membrane time constant based biphasic defibrillation waveforms. This comparison will result in identifying the optimal membrane time constant when programming the "tuned" defibrillation waveform.
Interventions
- DEVICE Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311181
The ClinicalTrials.gov registry entry for NCT00311181 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D) is the first listed.
NCT00311181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00311181 about?
NCT00311181 is a clinical study titled "POWER (Pulse Width Optimized Waveform Evaluation Trial)". The objective of this study is to compare the ULV (Upper Limit of Vulnerability)/DFT (Defibrillation Threshold) efficacy between the 2.5, 3.5 and 4.5 ms membrane time constant based biphasic defibrillation waveforms. This comparison will result in identifying the optimal membrane time constant when ...
What is the current status of trial NCT00311181?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 217 participants. The study started on 2006-08. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00311181?
The interventions under investigation include: Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D) (DEVICE).
Who is sponsoring clinical trial NCT00311181?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.